Nature Medicine, Published online: 29 September 2026; doi:10.1038/s41591-026-04693-z
In a phase 1 trial, inhibition of the Werner syndrome helicase (WRN) enzyme exploits a new synthetic lethal vulnerability in cancers with microsatellite instability, offering a new way to target these tumors beyond immune checkpoint inhibition.
